The program, scheduled to run from July 1, 2026, through December 31, 2027, offers eligible Medicare Part D members access to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy for a flat monthly cost of $50. By leveraging the Med+ platform, Weight Watchers intends to streamline the clinical process, handling the complex landscape of prior authorizations and insurance paperwork that often delays patient care.

Beyond prescribing, company clinicians will provide ongoing support, including nutrition guidance, medication tracking, and refill reminders. This holistic approach focuses on patient retention and side-effect management, ensuring that those enrolled in the bridge program remain adherent to their treatment plans throughout the eighteen-month window.